Ixchiq HCP

Menu
Menu

References

  1. IXCHIQ™ Product Monograph. June 20, 2024.
  2. IXCHIQ™ Data on File. 2024.
  3. World Health Organization. Chikungunya. Published December 8, 2022. Accessed March 13, 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/chikungunya.
  4. Craig J, et al. Diagnostic challenges in chikungunya infection. CCDR. 2015;41(1):6–10.
  5. World Health Organization. Chikungunya Overview. Accessed July 18, 2024. Available at: https://www.who.int/health-topics/chikungunya#tab=tab_1.
  6. Thiberville, SD, et al. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antivir Res. 2013 ;99(3):345–370.
  7. Sahadeo N, et al. Molecular characterisation of chikungunya virus infections in Trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases. PLoS Negl Trop Dis. 2015;9(11):e0004199.
  8. De Roo AM, et al. The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease. BMJ Glob Health. 2024;9:1–11.
  9. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl Trop Dis. 2021;15(3):e0009055.
  10. Centers for Disease Control and Prevention. Areas at risk for chikungunya. Updated November 8, 2024. Accessed January 16, 2025. Available at: https://www.cdc.gov/chikungunya/data-maps/index.html
  11. de Souza, et al. Pathophysiology of chikungunya virus infection associated with fatal outcomes. Cell Host Microbe. 2024;32:606–622.
  12. European Centre for Disease Prevention and Control. Chikungunya worldwide overview. January 16, 2025. Available at: https://www.ecdc.europa.eu/en/chikungunya-monthly.
  13. Boggild AK. et al. Chikungunya in travellers returning to Canada: Surveillance report from CanTravNet surveillance data, 2006 to 2015. J Assoc Med Microbiol Infect Dis Can. 2016;1(3):1–16.
  14. Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev. 2019;15:597–611.
  15. Centers for Disease Control and Prevention. Chikungunya in India. Accessed January 16, 2025. Available at: https://wwwnc.cdc.gov/travel/notices/level2/chikungunya-telangana-india.
  16. Staples JE, Hills S, Powers A. Chapter 4: Chikungunya/ In: Nemhauser J, ed. CDC Yellow Book 2024. Centers for Disease Control and Prevention. Accessed March 13, 2024. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/chikungunya.
  17. Bettis AA, et al. The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines. PLoS Negl Trop Dis. 2022;6(1):e0010069.
  18. Nemg Simo FB, et al. Chikungunya virus diagnosis: A review of current antigen detection methods. Trop Med Infect Dis. 2023;8(7):365.
  19. Pathak H, et al. Chikungunya arthritis. Clin Med. 2019;19(5):381–385.
  20. Silva L, Dermody T. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737–749.
  21. Paixão ES, et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;1123(7):301–316.
  22. Marques CDL, et al. Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 – Diagnosis and special situations. Rev Bras Reumatol. 2017;57(S2):S421–S437.
  23. Essackjee K, et al. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J. 2013;89(1054):440–447.
  24. World Health Organization. Guidelines on Clinical Management of Chikungunya Fever. Published October 2008. Accessed July 25, 2024. Available at: https://iris.who.int/bitstream/handle/10665/205178/B3234.pdf?sequence=1.
  25. Schneider M, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2023;401:2138–2147.
  26. Centers for Disease Control and Prevention. ACIP Recommendations. Updated March 6, 2024. Accessed April 18, 2024. Available at: https://www.cdc.gov/vaccines/acip/recommendations.html.
  27. Centers for Disease Control and Prevention. Factors to assess when considering use of chikungunya vaccine. Updated May 15, 2024. Accessed July 19, 2024. Available at: https://www.cdc.gov/chikungunya/media/pdfs/2024/05/Chikungunya-vaccine-risk-factors-508.pdf.
Valneva Canada Inc.
Commercial Operations
3535 Saint-Charles Blvd., Suite 600
Kirkland (Québec) H9H 5B9, Canada
Telephone: 514-630-6999